CLINICAL MANAGEMENT OF ASCUS/LSIL OF THE UTERINE CERVIX

ASCUS和LSIL临床处理的随机试验 子宫颈被设计为：l）确定人类是否 乳头瘤病毒（HPV）检测可以有效地分流妇女与细胞学检查， 诊断ASCUS（意义不明的非典型鳞状细胞） 或LSIL（低度鳞状上皮内病变）2）发展临床 管理指南，并为ASCUS提供预后信息， Bethesda系统的LSIL诊断类别，以及3）确定 筛选和处理潜在前体的费用 改善分流方法可减少子宫颈癌的病变。 承包商应建立研究协调和数据管理 试验股（CU）开发和维护系统和程序 生物医学数据管理、研究协调、统计 分析和报告写作。 协调股在其协调努力中应采取行动， 作为临床中心、质量控制组 研究顾问和国家癌症研究所项目官员。

The Randomized Trial on the Clinical Management of ASCUS and LSIL of the Uterine cervix is designed to: l) Determine whether human papillomavirus(HPV) testing can effectively triage women with a cytologic diagnosis of ASCUS (atypical squamous cells of undetermined significance) or LSIL (low-grade squamous intraepithelial lesion) 2) Develop clinical management guidelines and provide prognostic information for the ASCUS and LSIL diagnostic categories of the Bethesda System, and 3) Determine whether the cost of screening and treatment for the potential precursor lesions of cervical cancer can be reduced though improved triage. The Contractor shall establish a Study Coordinating and Data Management Unit (CU) for the Trial to develop and maintain systems and procedures needed for biomedical data management, study coordination, statistical analysis and report writing. The CU in its coordination efforts shall act as a liaison between the Clinical Centers, the Quality Control Groups, study consultants, and the National Cancer Institute Project Officers.